Isis Diabète

What Isis Diabète does

Isis Diabète, operating as part of ISIS Groupe, is a French family-owned home healthcare provider ('prestataire de santé à domicile') headquartered in Clichy, France. The company delivers expert at-home follow-up services for patients with chronic diseases treated by external medical pumps, organized into two poles: a diabétologie pole serving insulin pump and Hybrid Closed Loop system patients, and a neurologie pole (branded ISIS Parkinson and ISIS Immuno) serving patients with Parkinson's disease treated by apomorphine or Levodopa-Carbidopa-Entacapone intestinal infusion pumps, and patients with chronic inflammatory demyelinating polyradiculoneuropathy (PIDC) treated by immunoglobulin pumps. Its core offering is structured into branded follow-up programs — EXPERTIS® (expert in-home follow-up), INTENSIS® (intensive monitoring option), TÉLÉSIS® (remote follow-up for multiple daily injections), and DIÉTÉTIS® (dietetic support) — delivered by three dedicated expert field teams and supported by a 24/7 on-call service.

The company generates revenue through reimbursement from the French national health insurance system (Sécurité Sociale) and complementary insurers, billed per patient per care episode under the standard 'prestation de santé à domicile' model. Its go-to-market is prescriber-led: endocrinologists, neurologists, and other specialists refer patients via a dedicated 'Espace prescripteur' portal, and the company reinforces referral demand through medical congresses (JNLF, SFD), the RAPPID scientific webinar series, and an annual neurology congress. ISIS positions its independence from investment funds and listed groups as a strategic differentiator enabling long-term commitment to quality and continuity of care. Its technology is the chronic-pump care delivery model and supporting clinical workflows rather than a software or AI platform; no proprietary algorithms, APIs, or data products are described.

Name

Isis Diabète

Legal name

Isis Diabète

Website

https://isisdiabete.fr

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Isis Diabète is a French family-owned home healthcare provider that delivers expert at-home follow-up for patients with chronic diseases — diabetes, Parkinson's, and PIDC — treated by external medical pumps, reimbursed through the French national health insurance system.

Ownership category

akta.pro rank

Product category

Home Healthcare Services

NAICS

Health Care and Social Assistance (62)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Diabetes Education & Insulin Management (Home-Based) (HSABACAJ)

akta.pro secondary industries

Diabetes (General) (HLAKADAA), Type 1 Diabetes Care (HLAKADAB), Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

Keywords

• Home healthcare services
• Insulin pump therapy
• Diabetes care
• Parkinson care
• Chronic disease management

Headquarters

HQ city

Clichy

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Home Healthcare Services (Prestation de Santé à Domicile): ISIS provides reimbursed home healthcare services to patients with chronic diseases treated by external pumps. Revenue is generated through reimbursement from the French national health insurance system (Sécurité Sociale) and complementary health insurers, typical of the 'prestation de santé à domicile' model in France. Services are billed per patient per care episode, with ongoing follow-up protocols tied to specific therapeutic programs (EXPERTIS, INTENSIS, TÉLÉSIS, DIÉTÉTIS).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Isis Diabète is the diabétology pole of ISIS Groupe, a French home healthcare provider (prestataire de santé à domicile) that delivers tiered, expert at-home follow-up programs for patients with chronic diseases treated by external medical pumps. Core offerings center on EXPERTIS® expert pump follow-up, INTENSIS® intensive monitoring, TÉLÉSIS® remote teleconsultation follow-up for multiple daily injections, and DIÉTÉTIS® dietary support, all delivered by dedicated expert teams in patients' homes across France.

Product overview

Isis Diabète operates as a unified home healthcare platform with two specialized poles—diabétologie and neurologie—offering structured follow-up services. The diabétologie pole provides three tiered follow-up programs: EXPERTIS® and INTENSIS® for patients on external insulin pumps or Hybrid Closed Loop systems, and TÉLÉSIS® for patients on multiple daily injections, with DIÉTÉTIS® as an optional dietary support module. The neurology pole (ISIS PARKINSON and ISIS IMMUNO) delivers specialized care for Parkinson's disease and chronic inflammatory neurological conditions through similar structured follow-up programs including EXPERTIS®, INTENSIS®, and DIÉTÉTIS® options, with treatments including apomorphine pumps, Levodopa Carbidopa Entacapone pumps, and immunoglobulin pumps.

Differentiator

Problem solved

Functional benefit

Brands

• EXPERTIS®: Expert follow-up service for patients under insulin pump or apomorphine pump
• INTENSIS®
• TÉLÉSIS®
• DIÉTÉTIS®

Products and services

• EXPERTIS® Expert at-home follow-up service for patients with chronic diseases treated by external pumps (insulin pumps, apomorphine pumps, Levodopa-Carbidopa-Entacapone intestinal infusion pumps, or immunoglobulin pumps), delivered in France by dedicated field expert teams.
• INTENSIS® Intensive at-home follow-up option for patients on insulin pump or Hybrid Closed-Loop therapy (and selected neurology pump patients) requiring enhanced monitoring and support during pump therapy.
• TÉLÉSIS® Remote teleconsultation follow-up service for patients with diabetes on multiple daily insulin injections (MDI) who need distance-based monitoring and support outside of pump therapy.
• DIÉTÉTIS® Nutritional and dietetic support service for patients requiring dietary counseling as part of chronic disease management (diabetes, Parkinson's disease) under home healthcare.
• ISIS PARKINSON Specialized at-home healthcare service pole (within ISIS Groupe) for patients with Parkinson's disease, delivering expert follow-up for apomorphine pump and Levodopa-Carbidopa-Entacapone (Duodopa) intestinal infusion pump therapies.
• ISIS IMMUNO Specialized at-home healthcare service pole (within ISIS Groupe) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (PIDC) receiving pump-based subcutaneous immunoglobulin therapy.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Markets Duodopa/Duopa (Levodopa-Carbidopa-Entacapone intestinal gel) administered to Isis Parkinson's patients via home infusion pumps. Relevant to the therapy footprint but is a drug manufacturer rather than a home-care service provider.
• Clariane (formerly Korian): Major European home-care and nursing services network with French coverage and chronic disease home support offerings. Comparable in scale and home-based chronic care scope but with much wider service breadth than Isis's pump-focused positioning.
• Tandem Diabetes Care: U.S.-based insulin pump manufacturer (t:slim X2 with Control-IQ) expanding in Europe. Comparable in insulin-pump therapy focus but operating at the device manufacturer stage of the value chain rather than in clinical home support.
• VitalAire (Air Liquide Healthcare): Home healthcare subsidiary of Air Liquide delivering oxygen therapy, sleep apnea, ventilation, and diabetes services across France. Overlaps directly with Isis's PSAD infrastructure and Sécu reimbursement model but operates at materially larger scale with a broader therapeutic portfolio.
• Insulet: Manufacturer of the Omnipod patch insulin pump increasingly adopted by Isis's pump patients in France. Comparable in target therapy category but positioned as device manufacturer rather than home-support service provider.
• Medtronic: Global manufacturer of the MiniMed 780G insulin pump widely used by Isis patients. Comparable in diabetes pump therapy focus but operates at the device manufacturer layer rather than the home-care service layer.

Direct peers

• Elivie: A leading French home healthcare services provider covering chronic pathologies including diabetes and infusion therapies through the reimbursed PSAD model. Directly comparable to Isis Diabète in service offering, prescriber-led GTM, and home-delivery modality across France.
• Bastide Group: French listed group providing home medical services, respiratory care, and diabetes equipment distribution including the Confidis diabetes franchise serving insulin-pump patients. Highly comparable multi-pathology PSAD model with similar reimbursement structure.
• Orkyn': French home healthcare provider specializing in chronic disease management including insulin pump therapy, sleep, respiratory and nutrition services with reimbursed PSAD services. Direct competitor on the diabetes pump home support service line.
• SOS Oxygène Group: French PSAD primarily focused on home respiratory therapies (oxygen, ventilation, sleep) that also operates chronic-disease home services under the national reimbursement framework. Shares the prescribed, reimbursed, prescriber-referred home-care model with Isis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@isisdiabete1051/videos
• LinkedInlinkedin.com/company/isis-diab%C3%A8te
• Instagraminstagram.com/isis_diabete

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isis Diabète